stockrow
Friday 6 November 2026
Export ADPT’s income statement to Excel — free account
Adaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
26.83
0.00
0.00%
Follow ADPT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
8.90 | 7.31 | 11.13 | 15.56 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
1,199.01 | (226.34) | (535.76) | 482.62 | |
P/B ratio |
10.95 | 9.63 | 22.76 | 25.21 | |
Price to Tangible BV |
23.62 | 20.76 | 111.31 | 71.91 | |
EV/Sales |
8.87 | 7.31 | 11.10 | 15.68 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(53.40) | (79.84) | (162.76) | (1,092.24) | |
EV/FCF |
(50.17) | (73.09) | (142.28) | (529.53) | |
Quick Ratio |
3.08 | 3.06 | 4.49 | 3.69 | |
Current Ratio |
3.34 | 3.35 | 4.79 | 3.97 | |
Net Debt/EBITDA |
25.60 | 14.08 | 0.77 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 52.27% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 2.22 | 0.00 | |
Asset Turnover |
0.53 | 0.58 | 0.54 | 0.51 | |
Operating CF/Net income |
(0.15) | 0.48 | 0.16 | 3.34 | |
Capex/Depreciation |
(0.16) | (0.22) | (0.33) | 0.00 | |
Interest Coverage |
(4.32) | (6.65) | (5.85) | (0.91) | |
Research and Development Expense of Revenue |
30.36% | 33.33% | 26.77% | 22.21% | |
Selling, General and Administrative Expense of Revenue |
61.44% | 66.78% | 66.50% | 54.06% | |
Intangible Assets out of Total Assets |
0.24 | 0.24 | 0.19 | 0.17 | |
Share Based Compensation of Revenue |
17.75% | 16.83% | 15.54% | 12.38% | |
Graham Net Nets |
0.01 | 0.00 | (0.02) | (0.02) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.46%) | (2.38%) | (1.91%) | (1.56%) | |
Free Cash Flow Yield |
(1.99%) | (1.37%) | (0.70%) | (0.19%) | |
Revenue per Share |
0.47 | 0.46 | 0.45 | 0.52 | |
Operating CF per Share |
0.01 | (0.06) | (0.04) | 0.06 | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.01 | (0.07) | (0.05) | 0.05 | |
Cash per Share |
1.50 | 1.40 | 2.15 | 1.86 | |
Shareholders Equity per Share |
1.48 | 1.44 | 0.94 | 1.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.48 | 1.44 | 0.94 | 1.15 | |
Free Cash Flow |
1.42 | (10.33) | (7.58) | 7.68 | |
Working Capital |
210.27 | 204.80 | 332.85 | 293.72 | |
Capital Expenditures |
(0.64) | (0.80) | (1.18) | (1.93) | |
Net Current Asset Value |
12.45 | 10.11 | (69.45) | (106.54) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
46.05 | 45.95 | 46.90 | 55.75 | |
Average Payables |
6.87 | 7.99 | 6.07 | 8.40 | |
Average Inventory |
9.13 | 9.95 | 9.45 | 9.99 | |
Average Assets |
526.06 | 508.40 | 568.66 | 586.87 | |
Average Common Equity |
213.74 | 207.23 | 165.10 | 194.07 |
Columns are period end dates · fundamentals updated 4 Nov 2026